Oncolytics Biotech (TSE:ONC) Director Bernd Robert Seizinger Buys 40,000 Shares

Oncolytics Biotech Inc. (TSE:ONC) Director Bernd Robert Seizinger bought 40,000 shares of the business’s stock in a transaction that occurred on Thursday, February 12th. The shares were bought at an average price of C$1.17 per share, with a total value of C$46,800.00. Following the completion of the purchase, the director owned 566,991 shares in the company, valued at approximately C$663,379.47. The trade was a 7.59% increase in their ownership of the stock.

Bernd Robert Seizinger also recently made the following trade(s):

• On Wednesday, February 11th, Bernd Robert Seizinger bought 60,000 shares of Oncolytics Biotech stock. The stock was purchased at an average price of C$1.14 per share, for a total transaction of C$68,400.00.

Oncolytics Biotech Price Performance

Oncolytics Biotech Inc. has a 1 year low of C$0.44 and a 1 year high of C$2.08. The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86. The stock’s 50-day moving average is C$14.90 and its 200 day moving average is C$13.02. The firm has a market capitalization of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80.

Oncolytics Biotech (TSE:ONC) last announced its earnings results on Wednesday, November 12th. The company reported C($0.14) earnings per share for the quarter. As a group, research analysts expect that Oncolytics Biotech Inc. will post -0.41 EPS for the current year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.